US Stock MarketDetailed Quotes
TTOO T2 Biosystems
- 0.3650
- -0.0849-18.87%
Close Dec 13 16:00 ET
- 0.3800
- +0.0150+4.11%
Post 16:26 ET
7.68MMarket Cap-12.17P/E (TTM)
0.4550High0.3510Low2.05MVolume0.4364Open0.4499Pre Close786.59KTurnover25.75%Turnover RatioLossP/E (Static)21.04MShares8.379952wk High-0.66P/B2.90MFloat Cap0.351052wk Low--Dividend TTM7.95MShs Float122500.0000Historical High--Div YieldTTM23.12%Amplitude0.3510Historical Low0.3840Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
T2 Biosystems Stock Forum
GlobeNewswire· 6 mins ago
Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream
LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the "Company"), a leader in the rapid detection o...
T2 Biosystems (NASDAQ:TTOO) reported Q3 2024 financial results with total revenue of $2.0 million, up 34% year-over-year.
Sepsis test panel revenue reached $1.4 million, also increasing 34%.
The company secured 11 T2Dx® Instrument contracts and initiated an exclusive U.S. distribution agreement with Cardinal Health.
Net loss was $10.1 million ($0.57 per share), improving from $15.4 million loss in Q3 2023.
Cash position stood at $2.1 million as of September 30...
let's go sit at the bottom again
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. ...
No comment yet